Medline is the medical-supplies giant that completed the largest IPO of 2025, pricing at $29 per share on December 16, 2025 to raise about $6.26 billion and listing on the Nasdaq under the ticker MDLN, where it jumped more than 40% on its first day. Six months on, the Medline IPO has become a useful case study in how a profitable, debt-heavy, private-equity-owned healthcare distributor trades once the lockup hype fades — the stock has since drifted back below its debut close. This analysis breaks down the S-1, the financials, the named competitors, and how to get exposure to the medical-supply theme on MEXC.
Medline IPO Snapshot
| Field | Detail |
|---|---|
| Company | Medline Inc. |
| Ticker / Exchange | MDLN / Nasdaq |
| IPO Status (Phase) | Trading since December 17, 2025 (young listing) |
| IPO Price | $29 (priced near top of $26–$30 range) |
| Shares Offered | ~216 million Class A shares (+32.4M greenshoe) |
| Amount Raised (gross) | ~$6.26 billion (largest IPO of 2025) |
| Valuation at debut | ~$54 billion market cap (after +41% first day) |
| Lead Underwriters | Goldman Sachs, Morgan Stanley, BofA Securities, J.P. Morgan (40+ banks) |
| Revenue (FY2025) + Growth | $28.4 billion (+11.5% YoY) |
| Net Income (FY2025) | ~$1.2 billion |
| Long-term Debt | ~$12.5–12.8 billion (down from ~$16.8B; net leverage ~3.1x) |
| Owners (pre-IPO) | Blackstone, Carlyle, Hellman & Friedman (2021 LBO) |
| HQ / Founded | Northfield, Illinois / 1966 |
Table of Contents
- Key Takeaways
- What Is Medline?
- The Medline IPO: $29 Price, $6.26B Raise & 41% Pop
- Medline’s Financials From the S-1
- Who Are Medline’s Competitors?
- Medline IPO Bull Case vs Bear Case
- Medline Valuation vs Peers
- How Has MDLN Traded Since Its IPO?
- How to Buy Medline (MDLN) on MEXC
- Medline IPO FAQs
Key Takeaways
- What it does: Medline manufactures and distributes medical supplies — gloves, gowns, wound care, surgical kits and more — to hospitals, surgery centers, nursing homes and home-care providers across North America.
- IPO status: The Medline IPO priced at $29, raised ~$6.26 billion (the biggest listing of 2025), and the stock popped 41% to ~$41 on its December 17, 2025 Nasdaq debut as MDLN.
- Key financial stat: FY2025 revenue reached $28.4 billion (+11.5%), with roughly $1.2 billion of net income — a genuinely profitable business, unlike many recent IPOs.
- Bull angle: Scale, recurring demand, vertical integration and post-IPO deleveraging (net leverage cut to ~3.1x) make Medline a defensive, cash-generative healthcare compounder.
- Bear angle: A ~$12.5 billion debt load, tariff exposure of up to ~$375 million, thin distribution margins, and post-lockup share supply have weighed on MDLN since its debut.
What Is Medline?
Medline Inc., founded by the Mills family in 1966 and headquartered in Northfield, Illinois, is the largest privately built medical-supply company in the United States — now public after its December 2025 listing. It both manufactures and distributes hundreds of thousands of healthcare products: examination and surgical gloves, gowns and drapes, wound-care dressings, incontinence products, surgical kits, durable medical equipment and more. Its customers span the entire care continuum — acute-care hospitals, ambulatory surgery centers, physician offices, post-acute and long-term-care facilities, and home health. That breadth, plus a vast self-operated distribution network, is the core of Medline’s competitive position.
The strategic story behind the Medline IPO is vertical integration. Unlike pure distributors that simply move other manufacturers’ products, Medline designs and makes a large share of what it sells under its own brands, then delivers it through its own logistics. That dual role lets it capture both manufacturing and distribution margin, control quality and — critically after the pandemic — manage supply-chain resilience for essential medical goods. In 2021, Blackstone, Carlyle and Hellman & Friedman led a roughly $34 billion leveraged buyout of the company, one of the largest LBOs ever. The 2025 IPO was the exit and deleveraging event for that deal. For anyone searching “what does Medline do” or “is Medline publicly traded,” the answer is: Medline is a vertically integrated medical-products manufacturer-distributor that became a public company, ticker MDLN, in December 2025.
The Medline IPO: $29 Price, $6.26B Raise & 41% Pop
Medline priced its upsized IPO at $29 per share on December 16, 2025 — near the top of its $26–$30 marketed range — selling roughly 216 million Class A shares to raise about $6.26 billion. That made the Medline IPO the largest of 2025 globally. Underwriters were granted a 30-day option for an additional 32.4 million shares, and the bookrunning syndicate was led by Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan, with more than 40 banks involved. On its December 17 debut, MDLN opened strong and closed up more than 41% at roughly $41, valuing the company near $54 billion.
Two structural points matter for reading MDLN today. First, this was largely a deleveraging IPO: about $4 billion of proceeds went to paying down debt, cutting net leverage from roughly 4.9x to 3.1x — a deliberate balance-sheet repair rather than a growth-capital raise. Second, like most large private-equity exits, the float has expanded over time through follow-on and secondary offerings by selling stockholders (including launches of 60-million- and 75-million-share secondaries), which adds supply and has pressured the share price. Both help explain why a company that popped 41% on day one has since traded back toward — and below — its $29 offer price.
Medline’s Financials From the S-1
Unlike the loss-making tech names that dominate IPO headlines, Medline came public as a large, profitable enterprise. The S-1 and subsequent filings show fiscal-2025 revenue of about $28.4 billion, up 11.5% year over year, with net income of roughly $1.2 billion. Gross margin ran around 26.4% and operating margin near 7.8% — healthy for a business that is part manufacturer, part distributor, where the distribution side is inherently thin-margin and high-volume. This is a scale-and-efficiency story: Medline wins by being bigger, more vertically integrated and more logistically capable than rivals, not by commanding premium pricing.
The balance sheet is the swing factor. Coming out of the 2021 LBO, Medline carried roughly $16.8 billion of debt; the IPO and subsequent paydown brought total debt to about $12.8 billion and long-term debt near $12.5 billion, against just ~$1.9 billion of cash. Net leverage of ~3.1x is far more manageable than the post-buyout 4.9x, but it still means a meaningful slice of operating cash flow services interest rather than funding growth or buybacks. The filing also flags tariff exposure — Medline expects tariff-related costs of roughly $325–$375 million in fiscal 2025 and a further $150–$200 million in 2026, a direct hit to a company that imports a large share of its products. In short: solid, growing, cash-generative, but levered and tariff-exposed.
Who Are Medline’s Competitors?
Medline competes across two overlapping arenas: medical-product distribution and medical-product manufacturing. On the distribution side, its largest public rivals are the big three drug-and-medical distributors. McKesson stock is the largest U.S. healthcare distributor by revenue and the most direct scaled competitor. Cardinal Health stock runs a major medical and pharmaceutical distribution business and competes head-on in med-surg supply. Cencora stock (formerly AmerisourceBergen) rounds out the distribution oligopoly, though it skews more pharmaceutical.
On the dental, physician-office and specialty-distribution side, Henry Schein stock is a close comparable. And because Medline also manufactures, it overlaps with the big medical-device and consumables makers: Becton Dickinson stock in syringes, specimen collection and surgical products, and Baxter International stock in IV solutions, infusion and hospital products. Owens & Minor is another distribution peer, though privately less comparable in scale. Together these names form a tradeable map of the medical-supply chain — the same defensive, demand-stable theme the Medline IPO put back on investors’ radar.
Correlated & Competitor Stocks
| Company (Ticker) | What they do | Why correlated to Medline | Approx. price (early Jun 2026) |
|---|---|---|---|
| McKesson (MCK) | Largest U.S. healthcare distributor | Most direct scaled distribution competitor | ~$775 |
| Cardinal Health (CAH) | Medical & pharma distribution | Head-to-head in med-surg supply | ~$208 |
| Cencora (COR) | Pharma-led distribution | Third leg of the distribution oligopoly | ~$276 |
| Henry Schein (HSIC) | Dental & physician-office distribution | Specialty-distribution comparable | Low triple digits |
| Becton Dickinson (BDX) | Medical devices & consumables | Overlaps Medline’s manufacturing | ~$200s |
| Baxter International (BAX) | IV solutions, hospital products | Competes in hospital consumables | Mid-double digits |
Prices are approximate and as of early June 2026; verify the live quote before trading.
Medline IPO Bull Case vs Bear Case
The bull case. Medline sells essentials into one of the most demand-stable end markets there is: healthcare doesn’t pause for the economic cycle, and aging demographics steadily expand the need for medical supplies. Its vertical integration captures margin at two stages and gives it supply-chain control rivals lack. Scale brings purchasing power, distribution density and contract stickiness with large hospital systems. And the post-IPO deleveraging story is real — cutting net leverage to ~3.1x frees future cash flow and de-risks the balance sheet, potentially opening the door to dividends or buybacks over time. For investors who want defensive healthcare exposure with real earnings, MDLN is a rare profitable IPO.
The bear case, drawn from the S-1 risk factors. Leverage is still elevated: ~$12.5 billion of long-term debt means interest costs and refinancing risk remain front and center, especially if rates stay high. Margins are structurally thin on the distribution side, so a few points of cost inflation or pricing pressure matter. Tariffs are a concrete, quantified headwind — up to ~$375 million in fiscal 2025 — because Medline imports heavily. Private-equity overhang is another: Blackstone, Carlyle and Hellman & Friedman still hold large stakes, and their selling through secondary offerings adds share supply and has pressured the price. None of this breaks the thesis, but it explains why MDLN has underperformed its debut pop.
Medline Valuation vs Peers
How is the Medline IPO priced versus peers? At roughly $33–34 in early June 2026, MDLN sits below its $41 debut close and near its $29 offer price, for a market cap in the high-$40-billion-to-~$50-billion range on $28.4 billion of revenue — a bit under 2x sales, and a mid-to-high-teens multiple of earnings. That is broadly in line with, to slightly richer than, the big distributors: McKesson, Cardinal Health and Cencora trade on low price-to-sales ratios (distribution is a low-margin, high-turnover model) but more normalized earnings multiples. Medline’s vertical-integration and higher gross margin arguably justify a modest premium to the pure distributors, while its leverage argues for a discount to the cleaner-balance-sheet device makers like Becton Dickinson.
The honest, data-light read for a young listing: MDLN looks fairly-to-attractively priced relative to its growth and profitability, but the leverage and PE-overhang are the reasons it has not commanded a premium. This is not a buy or sell recommendation — it is the lens to judge MDLN by: a profitable, defensive compounder whose re-rating depends on continued deleveraging and the private-equity owners finishing their exit without flooding the market. Investors who prefer to spread the bet can size exposure across the distributor peers above rather than concentrate in a single recent listing.
How Has MDLN Traded Since Its IPO?
MDLN’s post-IPO path is a textbook example of debut euphoria meeting supply. After pricing at $29 and closing up ~41% near $41 on December 17, 2025, the stock has drifted back into the low-to-mid $30s by June 2026 — roughly its IPO price. Two mechanical forces dominate that tape. First, the standard ~180-day IPO lockup runs out around mid-June 2026, and the company’s private-equity owners have already launched multiple secondary offerings, steadily increasing the freely tradeable float. More shares chasing the same demand tends to cap price. Second, healthcare-distribution stocks are valued on steady earnings, not hype, so once the novelty faded, MDLN began trading like its lower-multiple distributor peers. For anyone watching MDLN, lockup expiry and the pace of PE selling are the near-term supply events that matter most, independent of the underlying business quality.
How to Buy Medline (MDLN) on MEXC
Because Medline is already trading, you can buy MDLN stock directly as real U.S. equity through MEXC’s RealStocks offering — actual shares, not a tokenized derivative. That makes MDLN one of the few recent large IPOs you can act on today rather than wait out a lockup, as with pre-IPO names. As always, this is access, not advice: position sizing and entry timing are your call, and the lockup-driven supply discussed above is worth factoring into any entry.
If your conviction is the broader medical-supply theme rather than Medline specifically, the correlated names give you diversified ways to play it: the distribution oligopoly through McKesson, Cardinal Health and Cencora; specialty distribution through Henry Schein; and the manufacturing side through Becton Dickinson and Baxter. These tend to move on the same drivers — hospital utilization, healthcare spending, drug-distribution volumes and tariff policy — and several are available as real U.S. shares through MEXC. Confirm live prices and size positions to your own risk tolerance before trading.
Medline IPO FAQs
What does Medline do?
Medline manufactures and distributes medical supplies — gloves, gowns, wound care, surgical kits, durable medical equipment and more — to hospitals, surgery centers, nursing homes, physician offices and home-care providers, primarily across North America.
Is Medline publicly traded, and what is the ticker?
Yes. Medline (ticker MDLN) has traded on the Nasdaq since December 17, 2025, after pricing its IPO at $29 per share and rising more than 40% on its first day.
How big was the Medline IPO?
Medline raised about $6.26 billion at $29 per share, the largest IPO of 2025 globally. It debuted at roughly a $54 billion market capitalization after a 41% first-day gain.
Who are Medline’s competitors?
Key public competitors include McKesson, Cardinal Health and Cencora in distribution; Henry Schein in specialty distribution; and Becton Dickinson and Baxter on the medical-manufacturing side. Owens & Minor is another distribution peer.
Why has MDLN stock fallen since its IPO?
Mainly supply and valuation. The ~180-day lockup and repeated private-equity secondary offerings expanded the float, while the market re-rated MDLN toward the lower earnings multiples of its distributor peers. Leverage and tariff costs add caution.
Disclaimer
This article is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation to buy any security. IPO details (price range, valuation, timing) are subject to change and may differ from the final terms. You cannot purchase shares of a company before it lists, and IPO allocations are not guaranteed. Past performance does not guarantee future results. Investors should read the company’s official SEC filings and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.